Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614069 Target Snapshot

A-431 · CELL-LINE · Homo sapiens

5,194Compounds
1,064Assays
55Approved Drugs
4,303.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats A-431 as ChEMBL target CHEMBL614069. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
A-431
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614069
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether A-431 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelA-431
UniProt AccessionN/A

A-431

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as A-431.

Review nameA-431
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

55
Approved
27
Phase III
25
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC504,032.0
EC50271.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2324630 10.74 IC50 0.018 Preclinical
CHEMBL1173655 10.64 IC50 0.023 Approved
CHEMBL292702 10.4 IC50 0.04 Clinical
CHEMBL2324629 10.19 IC50 0.064 Preclinical
CHEMBL94657 10.14 IC50 0.073 Clinical
CHEMBL126678 10.05 IC50 0.09 Preclinical
CHEMBL888 9.74 IC50 0.1831 Approved
CHEMBL2324627 9.72 IC50 0.19 Preclinical
CHEMBL153231 9.3 IC50 0.5 Preclinical
CHEMBL215032 9.26 IC50 0.55 Preclinical
Distribution

pChEMBL Value Distribution

637
5.0
559
5.5
374
6.0
245
6.5
184
7.0
122
7.5
48
8.0
32
8.5
14
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

DACOMITINIB ANHYDROUS
CHEMBL2110732
Approved 2018
BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NERATINIB
CHEMBL180022
Approved 2017
OSIMERTINIB
CHEMBL3353410
Approved 2015
AFATINIB
CHEMBL1173655
Approved 2013
CARFILZOMIB
CHEMBL451887
Approved 2009
TEMSIROLIMUS
CHEMBL1201182
Approved 2007
LAPATINIB
CHEMBL554
Approved 2007
VORINOSTAT
CHEMBL98
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
GEMCITABINE
CHEMBL888
Approved 1996
DOCETAXEL
CHEMBL3545252
Approved 1995
VINORELBINE
CHEMBL553025
Approved 1994
PACLITAXEL
CHEMBL428647
Approved 1992
AMSACRINE
CHEMBL43
Approved 1987
ETOPOSIDE
CHEMBL44657
Approved 1983
MITOMYCIN
CHEMBL105
Approved 1981
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
Approved 1974
DOXORUBICIN
CHEMBL53463
Approved 1974
FLUOROURACIL
CHEMBL185
Approved 1962
COLCHICINE
CHEMBL107
Approved 1961
Assay Landscape

Assay Landscape

1,064
Total Assays
2,600
Tested Compounds
4
Assay Types
Functional — 992 assays, 2,600 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 818 2,598 5.7
organism-based format 174 2 6.5
ADME — 46 assays, 175 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 45 175 5.5
organism-based format 1 0
Toxicity — 25 assays, 49 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 25 49 5.5
Unassigned — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine